Olivier D. Christophe

Inserm — France

Medicine · Health Sciences

42h-index6.0kcitations198works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(95), Hemophilia Treatment and Research(49), Blood Coagulation and Thrombosis Mechanisms(41), Blood groups and transfusion(38), Complement system in diseases(29)

Publications197 total

<i>Erratum</i> to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice”
Haematologica·2025Open Access
Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody
Blood·2025· 3 cited
A bispecific nanobody for the treatment of von Willebrand disease type 1
Blood·2025· 2 cited
Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice
Haematologica·2025· 3 citedOpen Access
Clinical, Phenotypic and Genotypic Characteristics of Von Willebrand Disease in Afro‐Caribbeans: Results From a Study in Martinique Island, French West Indies
Haemophilia·2025· 1 citedOpen Access
Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension
Haematologica·2024· 1 citedOpen Access
A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options
Haematologica·2024· 6 citedOpen Access
Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress
UNC Libraries·2024Open Access
Erratum to ‘Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress’ [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432]
UNC Libraries·2024Open Access
A consistent in vivo factor VIII-equivalence is unlikely to exist for non-factor therapies
SPIRE - Sciences Po Institutional REpository·2024
Fitusiran-treatment modulates the ratio between alpha- and beta-antithrombin isoforms
SPIRE - Sciences Po Institutional REpository·2024
How unique structural adaptations support and coordinate the complex function of von Willebrand factor
Blood·2024· 14 citedOpen Access
Erratum to ‘Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress’ [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432]
Research and Practice in Thrombosis and Haemostasis·2024Open Access
Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress
Research and Practice in Thrombosis and Haemostasis·2024· 5 citedOpen Access
Fitusiran displays efficient pro-hemostatic activity in a mouse model of inducible factor X-deficiency
SPIRE - Sciences Po Institutional REpository·2024
Fitusiran reduces bleeding in factor X–deficient mice
Blood·2024· 8 citedOpen Access
L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand
SPIRE - Sciences Po Institutional REpository·2024
Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
Haematologica·2023· 4 citedOpen Access
AAV-Mediated Expression of a Single-Chain FVIII Mimetic Antibody Efficiently Corrects Bleeding in Haemophilia a Mice
Blood·2023· 2 cited
PB1071 A Single-Domain Antibody Enhancing Protein S Activity Reduces Vaso-Occlusion in a Murine Model of Sickle Cell Disease
Research and Practice in Thrombosis and Haemostasis·2023Open Access
page 1 of 10Next →

Frequent Co-authors

Peter J. Lenting(26), Cécile V. Denis(23), Caterina Casari(9), Srini V. Kaveri(6), Sébastien Lacroix‐Desmazes(6), Paulette Legendre(6), François M. Vallette(5), Julie Pegon(5), Oleg Melnyk(5), Federico Mingozzi(4), Lisenn Lalier(4), Pierre‐François Cartron(4), Philip G. de Groot(4), Ana‐Maria Navarrete(4), Jagadeesh Bayry(4), Sandrine Delignat(4), Lisa Oliver(3), Suryasarathi Dasgupta(3), Bharath Wootla(3), Hélène Gras‐Masse(3)